Phase II Trial of Mitomycin-C in Squamous Cell Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study

Fifty-six patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix not previously exposed to cytotoxic drugs, other than as radiosensitizers, were entered into a study of single-agent 20 mg/m2 mitomycin-C every 6 weeks. The overall response rate among the 52 patients ev...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 1995-06, Vol.57 (3), p.376-379
Main Authors: Thigpen, Tate, Blessing, John A., Gallup, Donald G., Maiman, Mitchell, Soper, John T.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Biological and medical sciences
Carcinoma, Squamous Cell - drug therapy
Chemotherapy
Female
Humans
Medical sciences
Middle Aged
Mitomycin - adverse effects
Mitomycin - therapeutic use
Pharmacology. Drug treatments
Prognosis
Uterine Cervical Neoplasms - drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fifty-six patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix not previously exposed to cytotoxic drugs, other than as radiosensitizers, were entered into a study of single-agent 20 mg/m2 mitomycin-C every 6 weeks. The overall response rate among the 52 patients evaluable for response was 12% (three complete and three partial responses). Median response duration was 7.3 months. For the entire population, median progression-free interval was 3.0 months, and median survival was 4.9 months. Among 27 patients with pelvic disease only in previously radiated fields, two responses were observed (7%), whereas four responses were observed among 25 patients with extrapelvic disease in nonradiated fields (16%). The most frequent and severe adverse effects were the result of myelosuppression. Based on the modest level of activity observed, no further study of mitomycin-C in squamous cell carcinoma of the cervix is planned.
ISSN:0090-8258
1095-6859
DOI:10.1006/gyno.1995.1157